TRAW (Traws Pharma, Inc. Common Stock) Stock Analysis - Financials

Traws Pharma, Inc. Common Stock (TRAW) is a publicly traded Healthcare sector company. As of May 21, 2026, TRAW trades at $1.70 with a market cap of $26.67M and a P/E ratio of -0.94. TRAW moved +3.14% today. Year to date, TRAW is +25.58%; over the trailing twelve months it is +29.60%. Its 52-week range spans $0.97 to $19.44. Rallies surfaces TRAW's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are TRAW's key financials?

TRAW financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TRAW recently traded at $1.70. Market cap is $26.67M. P/E ratio is -0.94. Revenue is $2.73M.

TRAW Key Metrics

Key financial metrics for TRAW
MetricValue
Price$1.70
Market Cap$26.67M
P/E Ratio-0.94
EPS$-1.71
Dividend Yield0.00%
52-Week High$19.44
52-Week Low$0.97
Volume3.27K
Avg Volume0
Revenue (TTM)$2.73M
Net Income$-19.43M
Gross Margin0.00%

TRAW Annual Financials

YearRevenueNet IncomeEPS
2025$2.79M$9.17M$0.83
2024$226.00K$-166.52M$-35.21

Latest TRAW News

Recent TRAW Insider Trades

  • ORBIMED ADVISORS LLC bought 597.73K (~$998.21K) on Apr 16, 2026.

TRAW Analyst Consensus

TRAW analyst coverage data. Average price target: $0.00.

Common questions about TRAW

What are TRAW's key financials?
TRAW financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TRAW recently traded at $1.70. Market cap is $26.67M. P/E ratio is -0.94. Revenue is $2.73M.
Is TRAW research on Rallies investment advice?
No. Rallies provides research, data, and educational context for TRAW. It does not provide personalized investment advice.
TRAW

TRAW